Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

BACKGROUND: Diroximel fumarate (DRF) is approved for adults with relapsing–remitting multiple sclerosis (RRMS) in Europe and for relapsing forms of MS in the United States. DRF and dimethyl fumarate (DMF) yield bioequivalent exposure of the active metabolite monomethyl fumarate. Prior studies indica...

Descripción completa

Detalles Bibliográficos
Autores principales: Singer, Barry A, Arnold, Douglas L, Drulovic, Jelena, Freedman, Mark S, Gold, Ralf, Gudesblatt, Mark, Jasinska, Elzbieta, LaGanke, Christopher C, Naismith, Robert T, Negroski, Donald, Oh, Jiwon, Hernandez Perez, Miguel Angel, Selmaj, Krzysztof, Then Bergh, Florian, Wundes, Annette, Ziemssen, Tjalf, Castro-Borrero, Wanda, Chen, Hailu, Levin, Seth, Scaramozza, Matthew, Shankar, Sai L, Wang, Ting, Wray, Sibyl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687803/
https://www.ncbi.nlm.nih.gov/pubmed/37905526
http://dx.doi.org/10.1177/13524585231205708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687803/
https://www.ncbi.nlm.nih.gov/pubmed/37905526
http://dx.doi.org/10.1177/13524585231205708

Ejemplares similares